A predictive medicine to measure a patient’s exposure to 5-Fluorouracil (5-FU).

OnDose™ provides ongoing insight to help the physician proactively adjust and optimize dosing to maximize efficacy and reduce toxicity, and allows physicians to make a pharmacokinetic determination of the Area Under the Curve (AUC) for each infusion cycle. Studies have shown that 5-FU dosing based on pharmacokinetic determination of the AUC versus using standard Body Surface Area (BSA) dosing allows better optimization of treatment in patients receiving 5-FU infusion therapy.

Related Media

Myriad Genetics Launches OnDose™
Press Release; April 27, 2009